Tag: cardionovum
Drug-coated balloons: A “first-line” treatment for stenosis and vascular access failure...
This advertorial is sponsored by Cardionovum®
Matteo Tozzi (Varese, Italy) recently spoke to Vascular News about the role of drug-coated balloons (DCBs) in vascular access.
The...
Aperto® DCB: A breakthrough in prolonging dialysis access survival
This advertorial is sponsored by Cardionovum.
Cardionovum’s CE-marked Aperto drug-coated balloon (DCB) is, according to expert opinion and a growing evidence base, spearheading a revolution...
Vascular News’ top 10 most popular stories of June 2023
Highlights from this year’s Society for Vascular Surgery (SVS) Vascular Annual Meeting (VAM 2023; 14–17 June, National Harbor, USA) feature prominently in June's top 10.
1. “Sonolysis...
DCBs are “first-line treatment for better outcomes” for typical vascular access...
NOTE: This video is ONLY available to watch in selected countries and geographies
Could drug-coated balloons (DCBs) be “the perfect device” for the treatment...
The Aperto® drug-coated balloon: A “first-line” treatment for arteriovenous fistula lesions
This advertorial is sponsored by Cardionovum®.
In 2023, there are a number of different options available for treating the vascular access complications of thrombosis and...
APERTO DCB a “very promising new technology” for central vein stenosis
NOTE: This video is ONLY available to watch in selected countries and geographies
“Patients who are on chronic dialysis really depend on arteriovenous (AV)...
New study ‘adds to growing evidence of paclitaxel safety’
NOTE: This video is ONLY available to watch in selected countries and geographies
Matteo Tozzi (Varese, Italy) speaks to Vascular News at the Cardiovascular and Interventional...
Aperto® drug-coated balloon technology shows promise in dialysis access patients
This advertorial is sponsored by Cardionovum®.
The Aperto drug-coated balloon (DCB) technology (Cardionovum) is “one of the very promising new technologies” for treating central vein stenosis...
New data bolster safety and effectiveness of Safepax DCB coating technology
This advertorial is sponsored by Cardionovum®. DCB
Matteo Tozzi, associate professor of Vascular Surgery at the University of Insubria (Varese, Italy), speaks to Vascular News...
APERTO becomes the first drug-coated balloon to be approved in China...
APERTO, Cardionovum’s paclitaxel-coated balloon for arterio-venous access, has received market approval for China, making it the first high pressure drug-coated balloon (DCB) available in...
High-grade evidence supports use of APERTO DCB in vascular access stenosis
Jos van den Berg (Lugano, Switzerland) tells Vascular News at CIRSE 2019 that the results of the APERTO AVF China trial provide strong evidence of the benefits of...
Registry shows better patency and fewer reinterventions for Aperto drug-coated balloon...
Drug-coated balloon treatment for vascular access stenosis offers a real alternative to plain balloon angioplasty, reducing the rate of reinterventions and prolonging the lifespan of...
A New DCB Era of Safety and Efficacy
In this supplement: -SAFEPAX: No drug coating pitfalls -Why the RAPID trial is of clinical importance for a paradigm shift -Vascular access rescue with...
LEG-DEB registry reports encouraging six-month interim analysis for LegFlow
Six-month interim analysis of the Legflow drug-eluting balloon for the treatment of femoropopliteal occlusions (LEG-DEB) registry indicates that “the use of a new generation...
